Description
Accurate evaluation of half-life, ADCC, and ADCP is crucial for antibody drug development. Fc fragment binding to FcRn (FCGRT&B2M) predicts antibody half-life, while interactions with FcγRIIIa (CD16a) influence ADCC, and with FcγRIIa (CD32a)/FcγRIa (CD64) affect ADCP.
We offer a comprehensive range of Fc receptor products, including FcRn, FcγRs, their key variants, and TR-FRET–based Fc receptor binding kits, enabling precise and rapid assessment of these critical antibody functions.